NCT05337163View on ClinicalTrials.gov

A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China

CompletedOBSERVATIONAL
Enrollment

1,564

Participants

Timeline

Start Date

February 25, 2022

Primary Completion Date

February 18, 2025

Study Completion Date

March 5, 2025

Conditions
Lung CancerSmall Cell Lung CancerNon-Small Cell Lung CancerSquamous Cell CarcinomaAdenocarcinomaLarge Cell CarcinomaAdenosquamous CarcinomaSarcomatoid CarcinomaRespiratory Tract InfectionAcute BronchitisPneumoniaChronic BronchitisChronic Obstructive Pulmonary DiseaseTuberculosisLung NeoplasmPulmonary Interstitial Fibrosis
Interventions
DIAGNOSTIC_TEST

Diagnostic Test: Sputum DNA methylation analysis

Diagnostic Test: sputum specimen will be collected by the subject for the detection of Human Multigene Methylation Detection Kit (Fluorescent PCR Method)

PROCEDURE

chest CT or pathological examination

Subjects will undergo chest CT or pathological examination.

Trial Locations (1)

Unknown

Nanfang Hospital of Southern Medccal University, Guangzhou

All Listed Sponsors
collaborator

Guangzhou Xiangkang Medical Research Co., Ltd.

UNKNOWN

lead

Creative Biosciences (Guangzhou) Co., Ltd.

INDUSTRY